The impact of DMARD and anti-TNF therapy on functional characterization of short-term T-cell activation in patients with rheumatoid arthritis--a follow-up study.

by Balázs Szalay, Aron Cseh, Gergő Mészáros, László Kovács, Attila Balog, Barna Vásárhelyi
Published 2014-01-01

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy

by Sonja Dulic, Zsófia Vásárhelyi, Florentina Sava, László Berta, Balázs Szalay, Gergely Toldi, László Kovács, Attila Balog
Published 2017-01-01

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy

by Balázs Szalay, Gergő Mészáros, Áron Cseh, Lilla Ács, Magdolna Deák, László Kovács, Barna Vásárhelyi, Attila Balog
Published 2012-01-01

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

by Lorant Gonczi, Zsuzsanna Kurti, Mariann Rutka, Zsuzsanna Vegh, Klaudia Farkas, Barbara D. Lovasz, Petra A. Golovics, Krisztina B. Gecse, Balazs Szalay, Tamas Molnar, Peter L. Lakatos
Published 2017-08-01